Brief: Phio Pharmaceuticals Announces Initiation Of Collaborative Clinical Trial With PH-762, Agonox's Tumor Infiltrating Lymphocyte Program (AGX148) And Providence Cancer Institute
24/05/2023 12:36
May 24 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES INITIATION OF COLLABORATIVE
CLINICAL TRIAL WITH PH-762, AGONOX'S TUMOR INFILTRATING
LYMPHOCYTE PROGRAM (AGX148) AND PROVIDENCE CANCER INSTITUTE
* PHIO PHARMACEUTICALS CORP - TRIAL IS EXPECTED TO COMMENCE
IN
SECOND HALF OF 2023
Source text for Eikon: ID:nPn81gvRha
Further company coverage: PHIO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing